Director Genomics Shared Resource
- Institution
- ROSWELL PARK CANCER INSTITUTE CORP, NY
- Principal investigator
- Prashant Kumar Singh
- Funding
- $236K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY / ABSTRACT The current application seeks salary support for Prashant K. Singh, PhD who serves as the Director of the Genomics Shared Resource (GSR) at Roswell Park Comprehensive Cancer Center (Roswell Park) and Assistant Professor in the Department of Cancer Genetics and Genomics. Dr. Singh works closely with Cancer Center Support Grant (CCSG) leadership and members to provide a centralized, efficient approach of supporting research, clinical and population based genomic endeavors, while facilitating peer-reviewed funding, publications, and recruitment efforts. Dr. Singh supports all genomics initiatives at Roswell Park by providing expertise in all aspects of assay design, sample preparation, QC, data generation, and analyses. Dr. Singh acts as a subject matter expert for CCSG members utilizing genomics approached to acquire and analyze genomic data sets across basic, translational, clinical and population studies. Dr. Singh plays a vital role in discovery- driven research of CCSG members as well as in diagnostic applications that complement traditional clinical evaluation of cancer samples. Dr. Singh is involved in the research and design of NGS assays that support the goals of developing personalized therapies based on the unique genetic makeup of a patient’s cancer. The GSR is an integral part of Roswell Park’s CCSG (P30CA016056) for which the cancer center Director, Dr. Candace Johnson, serves as the Principal Investigator. In the current CCSG reporting period (2018-present), as of October 2023, 128 NIH/NCI grant applications utilizing the GSR services and Dr. Singh’s expertise were awarded to Roswell Park faculty. In the same period, the GSR contributed to 210 peer reviewed publications. Dr. Singh has over 19 years of experience in the field of genomics and epigenomics with a strong focus in cancer research. Dr. Singh actively participates in meetings focused on correlative sciences related to clinical trials, multi-PI, and multi-institutional programs such as the Roswell Park Ovarian SPORE (P50CA159981-08), P01 Program grant (P01CA234212), and the Western New York Center for Research on Flavored Tobacco Products (CRoFT, U54CA228110). Dr. Singh’s leadership and expertise is critical for continued success of the CCSG program and Roswell Park’s research mission. As the PI of Roswell Park’s CCSG (P30CA016056), Dr. Johnson will serve as the Unit Director for this R50 Core-based scientist (PAR-22-188) application.
LOADING MOONBASE SCORE
Questions for ROSWELL PARK CANCER INSTITUTE CORP
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Roswell Park Cancer Institute Corp69
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation
Brian C Betts · $712K · 2023–2028
- NIH · Roswell Park Cancer Institute Corp46
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies
Anna Bianchi-Smiraglia · $384K · 2020–2026
- NIH · Roswell Park Cancer Institute CorpNot yet scored
A scalable cruciferous vegetable intervention to reduce bladder cancer recurrence and progression
Li Tang · $717K · 2025–2029